Market Access · Pricing
The Right Price.
Sustainably.
Payer intelligence, pricing research, and negotiation support that positions your therapy for sustainable reimbursement at the right price.
PrimaryPayer Research
Overview
Engagement That Begins Years Before Launch
Payer engagement strategy begins years before launch — not at the first formulary submission. Sponsors who engage payers early, share evidence proactively, and understand the decision-making dynamics of each health system consistently achieve better reimbursement outcomes. Our pharma pricing strategy services combine primary payer intelligence with economic analysis to build a commercial access position that is defensible at every stage of the reimbursement process. The reference pricing linkages between global markets mean that a pricing decision made in one country affects what is achievable in others — we model these interdependencies from the start.
- Primary payer landscape intelligence
- Value-based, reference-aware pricing models
- Negotiation briefings from real payer behaviour
- Coordinated multi-market strategy
What We Deliver
Capabilities Across Every Stage
Three integrated disciplines, delivered by senior specialists as one accountable programme.
Payer Landscape Analysis
Payer landscape analysis is the foundation of every market access strategy we develop. We map the decision-making structure, evidence preferences, and historical reimbursement behaviour of relevant payers in each target market — integrating desk research with primary interviews. Market access pricing intelligence goes beyond list price comparisons; it captures net price dynamics, rebate structures, managed entry agreement precedents, and the specific evidence thresholds that have triggered positive and negative reimbursement decisions for therapies in the same class. Payer access consulting engagements identify the three to five evidence questions that will determine your reimbursement outcome in each market. Reimbursement consulting pharma experience across multiple therapy areas means we know which evidence gaps matter.
Pricing & Reimbursement Strategy
Pharma pricing strategy development begins with a value anchor — a clear articulation of what your therapy delivers that is relevant to each payer's decision framework. Pricing analysis pharma work combines willingness-to-pay research, cost-effectiveness threshold analysis, and reference pricing impact modelling to define a pricing range that is both commercially viable and reimbursement-achievable. Drug pricing strategy global modelling captures reference pricing linkages between markets and identifies launch sequencing that maximises net revenue without triggering adverse cascades. Value based pricing pharma approaches are increasingly expected by European payers. Health system pricing strategy considerations — affordability, budget impact, and managed access agreement structures — are integrated from the outset, not added as concessions during negotiation.
Negotiation Support
Payer negotiation pharma preparation is where market access intelligence translates into commercial outcome. We develop negotiation briefing documents that anticipate the specific challenges each payer is likely to raise — based on their historical behaviour and current budget environment. Reimbursement strategy pharma negotiation support covers formal price-volume discussions, managed entry agreement design, outcomes-based contract structuring, and appeals strategy. For sponsors seeking global payer strategy USA EU UK support across multiple simultaneous negotiations, we coordinate from a central team while providing jurisdiction-specific negotiation preparation — pharma pricing consulting worldwide.
6Global Regions
PrimaryPayer Interviews
IRA·AMNOGPBAC Experience
ISO 90012015 Quality System
Key Deliverables
What You Receive
Tangible, submission-ready outputs — not status updates.
Payer Landscape Report
Structured analysis of payer decision-making, evidence requirements, and competitive reimbursement context.
Pricing Model
Market-specific model capturing value-based pricing range, reference pricing implications, and net price projections.
Negotiation Briefing Document
Targeted preparation document covering anticipated payer challenges and recommended responses.
Why Vigilare
Why Sponsors Choose Vigilare
What sets this engagement apart from a generic vendor.
Primary Payer Research
Primary payer research capability — structured interviews with actual payer decision-makers in each major market, not desk-based secondary research applied to all jurisdictions.
Reference Pricing Modelling
Reference pricing modelling from day one of pricing strategy development — not retrospectively applied after a country launch has already set an unfavourable anchor price.
Behaviour-Based Briefings
Negotiation briefing documents built from real payer behaviour data — what specific agencies and committees have historically challenged, not generic objection-handling frameworks.
Market-Specific Capability
IRA price negotiation experience in the USA, AMNOG evaluation expertise in Germany, and PBAC negotiation support in Australia — market-specific capability, not generalised consulting.
Who We Work With
Configured to Your Model
We engage differently depending on the function you already have in place.
Commercial Market Access Leads
Challenge
Need a defensible pricing strategy that maximises value capture while securing broad reimbursement
How We Help
Evidence-based pricing strategy with market-specific scenarios, reference pricing analysis, and negotiation preparation.
Pre-Launch Programme Teams
Challenge
Planning pricing 18–24 months ahead of launch with incomplete real-world evidence
How We Help
Primary payer research to establish early price positioning and identify evidence generation priorities.
Post-Launch Pricing Challenges
Challenge
Facing mandatory price reviews, IRA negotiations, or reference pricing erosion
How We Help
Negotiation positions for price defence or managed entry agreement renegotiation.
FAQs
Payer Engagement & Pricing, Answered.
01
How to set drug pricing globally?
Global drug pricing requires understanding the value your therapy delivers relative to existing treatments in each market, the reference pricing linkages between markets, the evidence standards of each HTA body, and the negotiating dynamics of each payer. An effective global pricing strategy differentiates between list price positioning and net price outcomes, sequences country launches to protect against adverse reference pricing cascades, and builds value-based justification tailored to each major market's cost-effectiveness framework.
02
What is payer engagement in pharma?
Payer engagement involves building evidence-sharing relationships with the health insurance bodies, national health systems, and formulary committees that determine drug coverage and pricing. Effective payer engagement begins in the clinical development phase — shaping evidence generation to address the questions payers will ask at HTA — and continues through initial reimbursement, managed access, and post-launch price review.
Related Services
Complete the Access Strategy
Bundle this with the wider evidence and access programme — coordinated from one team.
Ready to optimize pricing?
Speak to our team about your programme requirements. We respond within one business day.